Pluri Secures China Patent for Large-Scale Immune Cell Manufacturing Technology
Pluri Inc. receives patent grant from China National Intellectual Property Administration for its proprietary 3D immune cell expansion and activation technology, expanding global IP protection across U.S., China, Japan, Korea, Australia and Israel.